{"entity":{"id":"clearnote-health","kind":"company","name":"ClearNote Health","aka":[],"tldr":"ClearNote Health sells blood tests that look for chemical marks on DNA fragments in the blood to catch pancreatic and ovarian cancer early in people at high risk.","summary":"ClearNote Health (formerly Bluestar Genomics) is a San Diego epigenomics company whose Avantect tests analyse cell-free DNA in plasma with a proprietary platform that captures epigenomic changes, combined with machine learning, to detect cancer signal in high-risk groups. The Avantect Pancreatic Cancer Test targets people with new-onset diabetes and other risk factors; an Avantect Ovarian Cancer Test and a multi-cancer detection programme are in development. The pancreatic test runs from a CLIA-certified, CAP-accredited laboratory, received a first in vitro diagnostic approval in July 2025 and a UK approval in September 2025, and validation data were shown at AACR, DDW and ASCO in 2026. In May 2026 the company closed a $52 million Series D led by founding investor Mattias Westman, with Sandy Weill and Stephen Quake participating, for over $185 million raised in total.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.clearnotehealth.com/"},{"label":"Series D press release (May 2026)","url":"https://www.clearnotehealth.com/clearnote-health-secures-52-million-in-series-d-financing-and-strengthens-leadership-team-to-accelerate-growth-in-early-cancer-detection/"},{"label":"Press release archive","url":"https://www.clearnotehealth.com/category/press-release/"}],"tags":[],"related":[],"cancers":["pancreatic","ovarian"],"sections":["early-detection","diagnostics"],"technologies":["liquid-biopsy","methylation-profiling","mced"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The 5-hydroxymethylcytosine (5hmC) basis of the platform is not stated on the fetched pages, so it is described generically as epigenomic. Earlier rounds (Series B, C) not sourced. Founding year not sourced."],"hq":"San Diego, CA","country":"US","companyType":"diagnostics","website":"https://www.clearnotehealth.com/","stage":"growth","investors":[],"funding":[{"round":"Series D","year":2026,"amountUsd":52000000,"source":"https://www.clearnotehealth.com/clearnote-health-secures-52-million-in-series-d-financing-and-strengthens-leadership-team-to-accelerate-growth-in-early-cancer-detection/","note":"Led by founding investor Mattias Westman; cumulative funding stated as over $185 million."}]},"route":"/companies/clearnote-health/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}]}}